Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on X:
“Trodelvy plus Keytruda shows significant PFS benefit vs chemo plus Keytruda in 1L PD-L1+ mTNBC (ASCENT-04).
First Phase 3 trial proving TROP-2 ADC plus IO combo superiority. Early OS benefit observed.”